bullous pemphigoid
Information
- Disease name
- bullous pemphigoid
- Disease ID
- DOID:8506
- Description
- "A pemphigoid that is characterized by large blisters." [url:https\://rarediseases.org/rare-diseases/bullous-pemphigoid/] {comment="sn:IEDB"}
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05267600 | Active, not recruiting | Phase 2/Phase 3 | A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid (BALLAD) | June 9, 2022 | March 28, 2025 |
| NCT04206553 | Active, not recruiting | Phase 2/Phase 3 | A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid | October 28, 2020 | January 21, 2025 |
| NCT05906706 | Available | Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid | |||
| NCT00525616 | Completed | Phase 3 | Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid | December 2008 | December 2013 |
| NCT00213421 | Completed | Comparison of Two Therapeutic Strategies of Dermoval in Treatment of Bullous Pemphigus | August 2001 | November 2008 | |
| NCT00809822 | Completed | Phase 2 | Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids. | November 2008 | October 2010 |
| NCT01408550 | Completed | Phase 3 | Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids | August 2011 | September 2013 |
| NCT05649579 | Completed | Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid | September 1, 2022 | January 31, 2023 | |
| NCT00431119 | Completed | Phase 2 | Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid | October 1997 | October 2000 |
| NCT02313870 | Completed | Phase 3 | Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid | January 22, 2008 | December 31, 2015 |
| NCT04117932 | Completed | Phase 2 | Efficacy and Safety of Ustekinumab in Bullous Pemphigoid | March 11, 2020 | June 22, 2023 |
| NCT00472030 | Completed | Phase 4 | Efficacy and Safety of Omalizumab in Bullous Pemphigoid | August 2007 | December 2010 |
| NCT04563923 | Completed | Phase 2 | Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody | October 10, 2020 | March 31, 2024 |
| NCT03320798 | Completed | Impact of Neurological Diseases on the Prognosis of Bullous Pemphigoid: A Retrospective Study of 178 Patients | October 1, 2013 | March 1, 2015 | |
| NCT00286325 | Completed | Phase 1/Phase 2 | Rituximab in the Treatment of Patients With Bullous Pemphigoid | March 2005 | March 2010 |
| NCT02837965 | Completed | Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid | September 26, 2013 | December 31, 2018 | |
| NCT04728854 | Completed | Telederm and Bullous Pemphigoid | March 15, 2021 | October 6, 2023 | |
| NCT02883894 | Completed | Interest of Dosage of Anti-PB230, Anti-PB180 and Cytokines for Monitoring of Patients Suffering From Bullous Pemphigoid | November 2009 | April 2014 | |
| NCT03099538 | Completed | Phase 2 | Ixekizumab in the Treatment of Bullous Pemphigoid | August 15, 2017 | June 6, 2019 |
| NCT03272958 | Completed | Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid | November 7, 2017 | October 3, 2018 | |
| NCT05366127 | Not yet recruiting | Validation of a Simplified Severity Score (Investigator Global Assessment: IGA) in Bullous Pemphigoid | July 1, 2022 | July 30, 2026 | |
| NCT04128176 | Not yet recruiting | Phase 3 | Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid | May 25, 2023 | November 25, 2023 |
| NCT06213909 | Recruiting | Retrospective Study of the Effects of Sub-pathologic Phenotypes of BP on Clinical Management and Prognosis | January 11, 2024 | June 30, 2024 | |
| NCT02753777 | Recruiting | Autoimmune Blistering Diseases Study | April 2016 | January 2, 2025 | |
| NCT03926377 | Recruiting | Phase 4 | Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid | April 1, 2019 | April 2024 |
| NCT05594472 | Recruiting | Phase 3 | Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid | November 1, 2022 | June 30, 2023 |
| NCT05681481 | Recruiting | Phase 3 | A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | March 22, 2023 | March 6, 2026 |
| NCT05984381 | Recruiting | Phase 4 | Efficacy and Safety of add-on Dapsone Versus add-on Methotrexate in Patients With Bullous Pemphigoid | August 1, 2023 | December 1, 2024 |
| NCT03286582 | Terminated | Phase 2 | A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid | September 5, 2017 | January 22, 2019 |
| NCT01688882 | Terminated | Phase 2 | Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment | January 2013 | March 2015 |
| NCT01571895 | Terminated | Phase 2 | Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid | February 20, 2012 | July 5, 2012 |
| NCT04612790 | Terminated | Phase 3 | A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid. | March 31, 2021 | October 26, 2023 |
| NCT02360202 | Unknown status | Phase 4 | Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid | April 2015 | December 2017 |
| NCT05284929 | Unknown status | Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population | May 17, 2017 | March 17, 2023 | |
| NCT03636763 | Unknown status | Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid? | September 2018 | December 2019 | |
| NCT01265082 | Unknown status | Explore the Mechanisms of Pruritus in Bullous Pemphigoid Patients During Remission | December 2010 | ||
| NCT04469582 | Unknown status | The Association of Bullous Pemphigoid With Dipeptidyl-peptidase 4 Inhibitors | April 1, 2009 | December 31, 2020 | |
| NCT00802243 | Unknown status | Phase 2 | Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid | September 2007 | |
| NCT04641884 | Unknown status | Bullous Pemphigoid Induced by antiPD-1/PDL-1 Therapy | April 1, 2020 | April 1, 2021 | |
| NCT02874079 | Unknown status | N/A | Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid | December 2015 | March 2018 |
| NCT05061771 | Withdrawn | Phase 3 | Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP) | May 6, 2022 | August 1, 2022 |
- Disase is a (Disease Ontology)
- DOID:0080841
- Cross Reference ID (Disease Ontology)
- GARD:5972
- Cross Reference ID (Disease Ontology)
- ICD10CM:L12.0
- Cross Reference ID (Disease Ontology)
- ICD9CM:694.5
- Cross Reference ID (Disease Ontology)
- MESH:D010391
- Cross Reference ID (Disease Ontology)
- NCI:C84389
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:77090002
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0030805
- OrphaNumber from OrphaNet (Orphanet)
- 703
- ICD10 preferred id (Insert disease from ICD10)
- D0009668
- ICD10 class code (Insert disease from ICD10)
- L12.0